Sharing Vaccine Expertise

BioNet has been committed to developing, manufacturing and delivering vaccines.

BioNet is a pioneering biotechnology group specialising in the development of next-generation vaccines.

The group has grown rapidly and now comprises companies, experts and senior teams spanning the Asia-Pacific region, Europe and North America. Our team of over 200 individuals is united by a commitment to innovation and excellence in advancing global health.

Our scientists are passionate about shaping the future of vaccine development. Our Scientific Advisory Board, chaired by Professor Emeritus Stanley Plotkin, oversees our innovation programmes.

Drawing on its expertise in translational research, BioNet has become the leading producer of recombinant pertussis vaccines and has recently demonstrated its excellence by obtaining EU GMP certification.

For over 20 years, BioNet has been fostering partnerships to advance global health, making an impactful contribution to various immunisation programmes and global polio eradication initiatives. Together, we are working towards a healthier and safer world.

A Laboratory Technician, Wearing a Mask, Analyzes Test Tubes and Operates a Microscope.

Key Achievements

Translational research until licensure of recombinant pertussis vaccine

Our 10-year clinical experience with pertussis vaccines

EU GMP manufacturing certificate for pertussis vaccine

R&D collaborations with leading universities and organizations

Contribution to public health vaccine programs through industry partnerships

Vision

To be a leading biotech organization, driving innovation and sharing expertise to ensure equitable access to vaccines worldwide.

Mission

“Our dream is a world free from preventable diseases. Our mission is to make this dream a reality.”

Quality Policy

BioNet commits to develop and manufacture innovative high-quality vaccines that comply with applicable regulatory requirements.

Committed to Excellence

At BioNet, we are dedicated to developing and manufacturing innovative, high-quality vaccines that meet and exceed regulatory requirements. Our commitment to excellence is reflected in our continuous pursuit of quality beyond compliance, ensuring that both our products and processes adhere to the highest standards through ongoing improvements to our quality systems.

Bionet workers test and inspect a vial packing machine where mRNA COVID19 vaccines will be produced after clinical trials are completed, at a factory in Ayutthaya, Thailand on 7, October, 2021. Bionet is a vaccine manufacturer that is producing Thailand’s mRNA COVID19 vaccine that was developed by a team from Chulalongkorn University.

 

Scientific Advisory Board

BioNet’s Scientific Advisory Board (SAB) comprises distinguished experts in vaccinology and infectious diseases, each bringing invaluable insights to the company’s mission of advancing vaccine development.

Stanley Plotkin

Emeritus Prof. of Wistar Institute and U Pennsylvania, Philadelphia

Jacques Francois Martin

Former President The Vaccine Fund

Nicole Guiso

Former Research Unit Head Institut Pasteur, Paris

Adam Finn

Prof. of Paediatrics, University of Bristol

William Gruber

Former SVP and Head of Pfizer Vaccine Clinical Research and Development

Norbert Pardi

Asst. Prof. of the Perelman School of Medicine, U Pennsylvania, Philadelphia

Peter Openshaw

Prof. of Experimental Medicine at Imperial College, London (via Imperial Consultants)